Clearside BioMedical Inc (CLSD):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Clearside BioMedical Inc (CLSD) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8237
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:55
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Clearside BioMedical Inc (Clearside) is a clinical biopharmaceutical company that develops treatments for vision impairment associated with uveitic macular edema. The company’s pipeline products comprise Uveitis, macular edema associated with non- infectious uveitis; RVO – Retinal Vein Occlusion and DME – Diabetic Macular Edema and wet age related macular degeneration (wet AMD). Clearside’s proprietary suprachoroidal treatment approach offers unprecedented access to the back of the eye where sight threatening disease often occurs. The company also offers services such as business development, license agreements and contract manufacturing services. It markets its products across the US. Clearside is headquartered in Alpharetta, Georgia, the US.

Clearside BioMedical Inc (CLSD) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Clearside BioMedical Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Clearside BioMedical Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Clearside BioMedical Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Clearside BioMedical Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Clearside BioMedical Inc, Medical Devices Deals, 2012 to YTD 2018 10
Clearside BioMedical Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Clearside BioMedical Inc, Pharmaceuticals & Healthcare, Deal Details 13
Venture Financing 13
Clearside Biomedical Raises USD0.3 Million in Venture Financing 13
Clearside Biomedical Raises USD20 Million in Series C Financing 14
Clearside Biomedical Raises USD16 Million in Series B Venture Financing 15
Clearside Biomedical Raises US$8 Million In Venture Financing 17
Clearside Biomedical Raises Additional Funds In Series A Financing 19
Partnerships 20
Clearside Biomedical Enters into Agreement with EyeKor 20
Santen Expands Research Agreement with Clearside Biomedical 21
Santen Enters Into Research Agreement With Clearside Biomedical 22
Licensing Agreements 23
NovaMedica Enters into Licensing Agreement with Clearside Biomedical 23
Clearside Biomedical Enters into Licensing Agreement with Emory University and GTRC 24
Equity Offering 25
Clearside Biomedical Prices Public Offering of Shares for USD85 Million 25
Clearside BioMedical Prices Public Offering of Shares for USD36 Million 27
Clearside Biomedical Raises USD50.4 Million in IPO 29
Clearside BioMedical Inc – Key Competitors 31
Clearside BioMedical Inc – Key Employees 32
Clearside BioMedical Inc – Locations And Subsidiaries 33
Head Office 33
Recent Developments 34
Financial Announcements 34
Aug 08, 2018: Clearside Biomedical announces second quarter 2018 financial results and provides corporate update 34
May 09, 2018: Clearside Biomedical Announces First Quarter 2018 Financial Results 37
Mar 14, 2018: Clearside Biomedical Reports Fourth Quarter 2017 Financial Results 38
Nov 08, 2017: Clearside Biomedical Announces Third Quarter 2017 Financial Results and Provides Corporate Update 41
Aug 09, 2017: Clearside Biomedical Announces Second Quarter 2017 Financial Results and Provides Corporate Update 43
May 10, 2017: Clearside Biomedical Announces First Quarter 2017 Financial Results and Provides Corporate Update 45
Mar 14, 2017: Clearside Biomedical Announces Fourth Quarter And Full Year 2016 Financial Results 47
Corporate Communications 49
Sep 27, 2018: Clearside Biomedical appoints Jeffrey Edwards to board of directors 49
Sep 11, 2018: Clearside Biomedical names Leslie Zacks as General Counsel and Chief Compliance Officer 50
Feb 26, 2018: Clearside Biomedical Appoints William Humphries As Board Chairman And Brion Raymond As Chief Commercial Officer 51
Aug 08, 2017: Clearside Biomedical Announces Changes to its Board of Directors 53
Jan 04, 2017: Clearside Biomedical Appoints Richard Beckman, M.D., as Chief Medical Officer 54
Appendix 55
Methodology 55
About GlobalData 55
Contact Us 55
Disclaimer 55

List of Tables
Clearside BioMedical Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Clearside BioMedical Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Clearside BioMedical Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Clearside BioMedical Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Clearside BioMedical Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Clearside BioMedical Inc, Medical Devices Deals, 2012 to YTD 2018 10
Clearside BioMedical Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Clearside Biomedical Raises USD0.3 Million in Venture Financing 13
Clearside Biomedical Raises USD20 Million in Series C Financing 14
Clearside Biomedical Raises USD16 Million in Series B Venture Financing 15
Clearside Biomedical Raises US$8 Million In Venture Financing 17
Clearside Biomedical Raises Additional Funds In Series A Financing 19
Clearside Biomedical Enters into Agreement with EyeKor 20
Santen Expands Research Agreement with Clearside Biomedical 21
Santen Enters Into Research Agreement With Clearside Biomedical 22
NovaMedica Enters into Licensing Agreement with Clearside Biomedical 23
Clearside Biomedical Enters into Licensing Agreement with Emory University and GTRC 24
Clearside Biomedical Prices Public Offering of Shares for USD85 Million 25
Clearside BioMedical Prices Public Offering of Shares for USD36 Million 27
Clearside Biomedical Raises USD50.4 Million in IPO 29
Clearside BioMedical Inc, Key Competitors 31
Clearside BioMedical Inc, Key Employees 32

List of Figures
Clearside BioMedical Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Clearside BioMedical Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Clearside BioMedical Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Clearside BioMedical Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Clearside BioMedical Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Clearside BioMedical Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Clearside BioMedical Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Clearside BioMedical Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Clearside BioMedical Inc, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[Clearside BioMedical Inc (CLSD):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Halfords Group plc (HFD):企業の戦略的SWOT分析
    Halfords Group plc (HFD) - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products a …
  • Wilson Therapeutics AB (WTX):製薬・医療:M&Aディール及び事業提携情報
    Summary Wilson Therapeutics AB (Wilson Therapeutics), a subsidiary of Alexion Pharma Nordics AB, is a biopharmaceutical company that develops novel therapies for patients with rare copper-mediated disorders. The company’s lead product includes WTX101 is a copper-protein-binding agent, which is used …
  • Waste Management Inc (WM):企業の財務・戦略的SWOT分析
    Waste Management Inc (WM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Enel SpA (ENEL):石油・ガス:M&Aディール及び事業提携情報
    Summary Enel SpA (Enel) is an integrated electricity and gas company that produces, distributes and trades electricity and natural gas. The group generates electricity using diverse sources of energy such as nuclear, renewables, oil and gas turbine, coal and gas combined cycle. It also focuses on di …
  • Teekay Offshore Partners L.P.:企業のM&A・事業提携・投資動向
    Teekay Offshore Partners L.P. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Teekay Offshore Partners L.P. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and …
  • Shanghai Jin Jiang International Hotels (Group) Co Ltd:企業の戦略・SWOT・財務情報
    Shanghai Jin Jiang International Hotels (Group) Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Shanghai Jin Jiang International Hotels (Group) Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company' …
  • Condor Petroleum Inc (CPI):石油・ガス:M&Aディール及び事業提携情報
    Summary Condor Petroleum Inc. (Condor) is an independent upstream oil and gas company. The company through its subsidiaries, acquires, explores, produces and markets oil and gas. It has operational presence in Kazakhstan and Turkey. The company operates on the Pre-Caspian basin, a prolific region th …
  • Domtar Corp (UFS):企業の財務・戦略的SWOT分析
    Domtar Corp (UFS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Enanta Pharmaceuticals Inc (ENTA):企業の財務・戦略的SWOT分析
    Summary Enanta Pharmaceuticals Inc (Enanta) is a biotechnology company that discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. The company’s lead product candidate includes EDP-305, a farnesoid X receptor (FXR) agonist intended for the treatment of …
  • Jaya Tiasa Holdings Berhad (JTIASA):企業の財務・戦略的SWOT分析
    Jaya Tiasa Holdings Berhad (JTIASA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Ralph Lauren Corporation:戦略・SWOT・企業財務分析
    Ralph Lauren Corporation - Strategy, SWOT and Corporate Finance Report Summary Ralph Lauren Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • The Kansai Electric Power Company Inc (9503)-エネルギー分野:企業M&A・提携分析
    Summary The Kansai Electric Power Company Inc (KEPCo) is an integrated power utility. The company produces and supplies electricity; and procures and sells natural gas. It generates electricity from natural gas, oil, nuclear, coal, hydro, wind, and solar sources. Through long, medium, and short term …
  • Nine Dragons Paper (Holdings) Limited:戦略・SWOT・企業財務分析
    Nine Dragons Paper (Holdings) Limited - Strategy, SWOT and Corporate Finance Report Summary Nine Dragons Paper (Holdings) Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analy …
  • Biomatrica Inc:医療機器:M&Aディール及び事業提携情報
    Summary Biomatrica Inc (Biomatrica) is a developer, manufacturer, and supplier of stability technologies preserve biological materials. The company offers DNA, RNA, proteins, cells, and entire assays for diagnostics, research, forensics, biobanks, and sustainability applications. Its products includ …
  • Diffusion Pharmaceuticals Inc (DFFN):企業の財務・戦略的SWOT分析
    Summary Diffusion Pharmaceuticals Inc (Diffusion), formerly Diffusion Pharmaceuticals LLC is a clinical stage biotechnology company that develops standard of care therapies. The company improves cancer treatments such as radiation therapy and chemotherapy in treatment-resistant solid tumors, includi …
  • Omnicell Inc (OMCL)-医療機器分野:企業M&A・提携分析
    Summary Omnicell Inc (Omnicell) is a provider of automation and business analytics software solutions. It provides medication control and patient safety solutions to enhance operational efficiency and patient care in acute healthcare facilities. The company offers automation solutions such as medica …
  • Boston Scientific Corp (BSX):医療機器:M&Aディール及び事業提携情報
    Summary Boston Scientific Corp (Boston Scientific) is a medical device company that develops, manufactures and markets devices used in a range of interventional medical procedures. The company offers products in seven business groups, namely, Interventional Cardiology, Cardiac Rhythm Management (CRM …
  • Varian Medical Systems Inc (VAR):企業の財務・戦略的SWOT分析
    Varian Medical Systems Inc (VAR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • M1 Ltd:企業の戦略的SWOT分析
    M1 Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. This …
  • Okklo Life Sciences BV:製薬・医療:M&Aディール及び事業提携情報
    Summary Okklo Life Sciences BV (Okklo) is a biopharmaceutical company that develops novel therapeutic solutions. The company offers cyclodextrin-based medicines for the treatment of neglected and orphan diseases. It also develops therapeutics for infectious diseases and lysosomal storage diseases. O …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆